ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Frequency and Determinant Factors for Calcification in Neurocysticercosis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Monoclonal antibody-based immunohistochemistry reveals residual Taenia solium antigens in calcified granulomas from pigs with neurocysticercosis.PLoS neglected tropical diseases · 2026Article
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- When the Past Catches Up: A Case of Latent Neurocysticercosis Presenting With Seizures.Cureus · 2026Article
- Frequency and characteristics of cognitive impairment in individuals with calcified neurocysticercosis.Clinical neurology and neurosurgery · 2025Article
- Identification of abnormal patterns of evolution of neurocysticercosis cysts and what they might indicate.medRxiv : the preprint server for health sciences · 2025Article
- Calcified Neurocysticercosis: Understanding Dead (Not Necessarily Inactive) Parasites.The American journal of tropical medicine and hygiene · 2025Review
- The process of residual calcification following antiparasitic treatment in the pig model of neurocysticercosis is dynamic.PLoS neglected tropical diseases · 2025Article
- Albendazole and praziquantel combination versus albendazole alone in children with multiple neurocysticercosis: An open labelled randomized controlled trial.Journal of family medicine and primary care · 2024Article
- Massive neurocysticercosis in a ten-year-old girl: a case report.BMC pediatrics · 2024Article
- Epilepsy Due to Solitary Calcified Cysticercus Granuloma.Pathogens (Basel, Switzerland) · 2023Article
- New animal models of neurocysticercosis can help understand epileptogenesis in neuroinfection.Frontiers in molecular neuroscience · 2022Article
- Incidence of Adult-Onset Epilepsy and the Contributory Role of Neurocysticercosis in a Five-Year, Population-Based, Prospective Study in Rural Ecuador.The American journal of tropical medicine and hygiene · 2021Article
- Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world.Journal of the neurological sciences · 2021Review
- Parasitic Infections of the Nervous System.Continuum (Minneapolis, Minn.) · 2021Review
- Mortality in Parenchymal and Subarachnoid Neurocysticercosis.The American journal of tropical medicine and hygiene · 2021Article
- [Reactivation of neurocysticercosis in patient under study on suspicion of dengue].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
Abstract
backgroundNeurocysticercosis is a major cause of acquired epilepsy. Larval cysts in the human brain eventually resolve and either disappear or leave a calcification that is associated with seizures. In this study, we assessed the proportion of calcification in parenchymal neurocysticercosis and risk factors associated with calcification.
methodsData for 220 patients with parenchymal NCC from 3 trials of antiparasitic treatment were assessed to determine what proportion of the cysts that resolved 6 months after treatment ended up in a residual calcification at 1 year. Also, we evaluated the risk factors associated with calcification.
resultsThe overall proportion of calcification was 38% (188/497 cysts, from 147 patients). Predictors for calcification at the cyst level were cysts larger than 14 mm (risk ratio [RR], 1.34; 95% confidence interval [CI], 1.02-1.75) and cysts with edema at baseline (RR, 1.39; 95% CI, 1.05-1.85). At the patient level, having had more than 24 months with seizures (RR, 1.25; 95% CI, 1.08-1.46), mild antibody response (RR, 1.14; 95% CI, 1.002-1.27), increased dose albendazole regime (RR, 1.26; 95% CI, 1.14-1.39), lower doses of dexamethasone (RR, 1.36; 95% CI, 1.02-1.81), not receiving early antiparasitic retreatment (RR, 1.45; 95% CI, 1.08-1.93), or complete cure (RR, 1.48; 95% CI, 1.29-1.71) were associated with a increased risk of calcification.
conclusionsApproximately 38% of parenchymal cysts calcify after antiparasitic treatment. Some factors associated with calcification are modifiable and may be considered to decrease or avoid calcification, potentially decreasing the risk for seizure relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.